Stockley Park, Uxbridge, PA, United States of America

Swethajit Biswas

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Springworks Therapeutics, Inc.. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Swethajit Biswas. Retrieved from https://idiyas.com/inventor/swethajit-biswas-5447lvie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

% Patents Active = 100.0

 

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Swethajit Biswas and His Patent in Cancer Therapy

Introduction

Swethajit Biswas is an inventor associated with Stockley Park, Uxbridge, Pennsylvania, United States. His patent work includes an invention concerning combination therapy for cancer treatment.

Latest Patents

Biswas is listed as an inventor on 1 patent: “Combination Therapy with an Anti-BCMA Antibody and a Gamma Secretase Inhibitor.” The patent describes combining an antibody targeting B-cell maturation antigen (BCMA) with a gamma secretase inhibitor.

Career Highlights

The supplied information associates Biswas with SpringWorks Therapeutics, Inc., and GlaxoSmithKline Intellectual Property Development Limited. These organizations are connected with his professional and patent-related background.

Collaborations

Biswas’s listed coworkers include Katarina Luptakova and Beata Holkova. Their names appear alongside his in the context of his professional and patent work.

Conclusion

Swethajit Biswas’s recorded patent focuses on a combination approach involving an anti-BCMA antibody and a gamma secretase inhibitor, reflecting his contribution to cancer-therapy innovation.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…